Clinical Trials on Relapsed Refractory Multiple Myeloma

Total 4746 results

Amgen

Active, not recruiting

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia

United States, Australia, Japan, Germany, Canada
Novartis Pharmaceuticals

Completed

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (MACS1271)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple Myeloma

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic Leukemia

United Kingdom, Spain, France, Australia
University of Nebraska
M.D. Anderson Cancer Center

Terminated

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma

United States
Alfred Chung, MD
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Multiple Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Oncopeptides AB

Terminated

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma (LIGHTHOUSE)

Relapsed Multiple Myeloma | Relapsed-Refractory Multiple Myeloma

Serbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
All4Cure
GlaxoSmithKline

Recruiting

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma, Refractory

United States
Carl Ola Landgren, MD, PhD
Bristol-Myers Squibb

Recruiting

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (Iber-KDd)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Amgen

Completed

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

Canada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
Regeneron Pharmaceuticals

Active, not recruiting

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; H. Lee Moffitt...

Completed

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Takeda

Completed

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States, Canada
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
Thomas Martin, MD
Bristol-Myers Squibb; Janssen Research & Development, LLC

Not yet recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Cartesian Therapeutics

Recruiting

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (DC15-MM-01)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Thomas Martin, MD
University of California, Davis; Actavis Inc.; Eugia Pharma Specialities Limited

Recruiting

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Andrew Yee, MD
Bristol-Myers Squibb; Takeda Pharmaceuticals North America, Inc.

Terminated

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Thomas Martin, MD

Withdrawn

Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma
Genentech, Inc.

Completed

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

Belgium, Australia, Denmark, Norway
Tulane University School of Medicine
Karyopharm Therapeutics Inc

Withdrawn

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma (ESdRRMM)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma
Instituto de Seguridad y Servicios Sociales de...

Unknown

Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans (MM-POM-2018)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

Mexico
Multiple Myeloma Research Consortium

Not yet recruiting

Horizon Adaptive Platform Trial Evaluating Therapies in RRMM

Refractory Multiple Myeloma | Relapse Multiple Myeloma
Massachusetts General Hospital
Pfizer

Recruiting

Elranatamab in R/R Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
Pfizer

Recruiting

A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases (MUST)

Refractory Multiple Myeloma | Relapse Multiple Myeloma

Italy
Shenzhen University General Hospital

Recruiting

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Black Sea Hematology Association
Amgen

Unknown

Carfilzomib in Combination for the Treatment of RR MM

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

Turkey
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Weill Medical College of Cornell University
Janssen Scientific Affairs, LLC

Recruiting

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
Ajai Chari
Amgen

Completed

Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
Medical College of Wisconsin

Recruiting

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (EMBRACE)

Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic

Completed

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
The First Affiliated Hospital of Xiamen University

Recruiting

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Oncotherapeutics

Not yet recruiting

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Dong-A University Hospital

Not yet recruiting

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM (KMM-KCd)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Amsterdam UMC, location VUmc

Not yet recruiting

Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study (POMAlternative)

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Tel-Aviv Sourasky Medical Center
Weizmann Institute of Science

Recruiting

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

Israel
Tel-Aviv Sourasky Medical Center

Recruiting

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (IPoD-790)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse

Israel
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China

Clinical Trials on Relapsed Refractory Multiple Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations